Akebia Therapeutics

385 articles about Akebia Therapeutics

• AkebiaShares Program: Current Approaches for Managing Hyperphosphatemia and Caring for Patients via Telehealth

  12/9/2020

  Virtual Panel of Nephrology Care Professionals to Share Insights and Experiences Managing Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis   [09-December-2020]   CAMBRIDGE, Mass. , Dec. 9, 2020 /PRNewswire/ --  Akebia Therapeutics, Inc.  (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disea

• Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Dec 02, 2020

  12/2/2020

  Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 7 newly-hired employees options to purchase an aggregate of 49,000 shares of Akebia's common stock on November 30, 2020, as inducements material to each such employee's entering into employment with Akebia.

• Akebia Therapeutics to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference

  11/24/2020

  Akebia Therapeutics, Inc.  (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will participate in the Piper Sandler 32 nd Annual Virtual Healthcare Conference.

• Akebia Therapeutics Ranked 10th Fastest-Growing Company in North America on Deloitte's 2020 Technology Fast 500™

  11/18/2020

  Akebia Therapeutics, Inc.  (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it ranked number 10 on Deloitte's Technology Fast 500™ , a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences and energy tec

• Akebia Announces Manuscript Highlighting Global Phase 3 INNO2VATE Program Rationale, Study Design and Baseline Characteristics Published in Peer-Reviewed Medical Journal

  11/16/2020

  Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the publication of a manuscript detailing the study design and methodology for its global Phase 3 INNO2VATE program in Nephrology Dialysis Transplantation (NDT),

• Akebia Reports Third Quarter 2020 Financial Results and Recent Business Updates

  11/5/2020

  Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose of bettering the lives of people impacted by kidney disease, today reported financial results for the third quarter ended September 30, 2020 and provided business updates, including confirming completion of a pre-NDA meeting with the U.S. Food and Drug Administration (FDA) for vadadustat.

• Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Nov 03, 2020

  11/3/2020

  Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 6 newly-hired employees options to purchase an aggregate of 27,000 shares of Akebia's common stock on October 30, 2020, as inducements material to each such employee's entering into employment with Akebia.

• Akebia Therapeutics to Report Third Quarter 2020 Financial Results and Discuss Recent Business Highlights

  10/26/2020

  Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results for the third quarter ended September 30, 2020 , on Thursday, November 5, 2020 before the opening of the financial markets.

• Akebia Presents Results from its PRO2TECT Global Phase 3 Program of Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients Not on Dialysis

  10/23/2020

  Akebia Therapeutics, Inc. (Nasdaq: AKBA), today announced the presentation of clinical data from its PRO2TECT global Phase 3 program that evaluated the efficacy and safety of vadadustat, Akebia's investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI)

• Akebia Presents Results from its INNO2VATE Global Phase 3 Program; Demonstrated Efficacy and Cardiovascular Safety of Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis

  10/22/2020

  - INNO2VATE data presented at American Society of Nephrology Kidney Week 2020 Reimagined - Presentation expands on previously announced positive top-line data showing vadadustat achieved clear and consistent results across primary and secondary efficacy and safety endpoints - Company on track to submit New Drug Application - Company to host investor briefing webcast at 4:10 p.m. ET on October 23, 2020

• Akebia to Present Global Phase 3 Vadadustat Data at American Society of Nephrology Kidney Week 2020 Reimagined

  10/9/2020

  - Phase 3 data from INNO2VATE program in dialysis and PRO2TECT program in non-dialysis accepted for oral presentation - Ten additional abstracts accepted - Company to host investor briefing webcast at 4:10 p.m. ET on October 23, 2020   [09-October-2020]   CAMBRIDGE, Mass. , Oct. 9, 2020 /PRNewswire/ --  Akebia Therapeutics ® , Inc. (Nasdaq: AKBA) toda

• Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Oct 02, 2020

  10/2/2020

  Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 11 newly-hired employees options to purchase an aggregate of 84,000 shares of Akebia's common stock on September 30, 2020, as inducements material to each such employee's entering into employment with Akebia.

• Akebia Therapeutics Announces September 2020 Investor Conference Schedule

  9/8/2020

  Akebia Therapeutics, Inc.  (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will participate in the following virtual investor conferences in September. 

• Akebia Therapeutics Announces Top-Line Results from its PRO2TECT Global Phase 3 Program of Vadadustat for Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients Not on Dialysis

  9/3/2020

  Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, announces top-line results from PRO2TECT, the second of its two global Phase 3 cardiovascular outcomes programs.

• 

  Akebia’s Vadadustat Hits Efficacy, Failed Safety Endpoints in Kidney Disease Trials

  9/3/2020

  Akebia Therapeutics announced topline results for PRO2TECT, the second of two Phase III cardiovascular outcomes programs. The trial was evaluating the company’s vadadustat for treatment of anemia caused by chronic kidney disease in adults not on dialysis.

• Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sep 02, 2020

  9/2/2020

  Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 10 newly-hired employees options to purchase an aggregate of 54,000 shares of Akebia's common stock on August 31, 2020, as inducements material to each such employee's entering into employment with Akebia.

• Akebia Therapeutics Announces First Commercial Launch of VAFSEO™ (vadadustat tablets), a New Oral Treatment for Anemia Due to Chronic Kidney Disease, in Japan

  8/26/2020

  VAFSEO Launch Marks Availability of Convenient Once-Daily Oral Treatment for Adult Patients on Dialysis and Not on Dialysis in Japan

• Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 04, 2020

  8/4/2020

  Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted four newly-hired employees options to purchase an aggregate of 23,500 shares of Akebia's common stock on July 31, 2020, as inducements material to each such employee's entering into employment with Akebia.

• Akebia Therapeutics to Report Second Quarter 2020 Financial Results

  8/3/2020

  Company announces database lock and plans to report top-line data from global Phase 3 PRO2TECT program of vadadustat for treatment of anemia due to chronic kidney disease in adult patients not on dialysis

• Akebia Announces Initiation of Investigator-Sponsored Study Evaluating Vadadustat for Prevention and Treatment of ARDS in Patients Hospitalized with COVID-19

  7/14/2020

  The University of Texas Health Science Center at Houston to conduct study with up to 300 patients to evaluate use of Akebia's investigational drug, vadadustat, as potential therapy to lessen the severity of COVID-19